Tag: pharma

Liabilities of an Infringer in an Infringement Suit: A Case Analysis

17th December, 2021 - 11:07 am Categories: Intellectual Property

Introduction: In the recent judgment of the Delhi High Court dated 13th December 2021, it was observed that “When an infringer seeks to defend patent infringement on the ground that the patent is invalid, the onus to prove the invalidity of patent lies heavily on an infringer and this standard has to be met when … Continue reading Liabilities of an Infringer in an Infringement Suit: A Case Analysis

Read more »

Double Patenting and Where it Stands as per Delhi High Court

15th July, 2021 - 5:12 am Categories: Legal Issues

In a recent Judgement by Delhi High Court on 02.11.2020 (CS (Comm) 410/2020 AstraZeneca Ab & Anr v Alkem Laboratories), AstraZeneca (Plaintiff), a reputed British-Swedish multinational Pharmacy & Biotechnology company, was denied an Application under Order 39 Rule 1 &2 under the CPC for grant of Temporary Injunction against Alkem Laboratories (Defendants). It was contended … Continue reading Double Patenting and Where it Stands as per Delhi High Court

Read more »

NATCO FILES INDIA’S FIRST COMPULSORY LICENSING APPLICATION

14th September, 2011 - 4:38 am Categories: Patent Commercialisation Pharma- biotech- Patent Commercialisation

Natco Pharma has filed India’s first Compulsory Licensing (CL) Application (in accordance with Section 84(1) of the Indian Patents Act) against one of the Bayer’s patented drug Sorafenib, marketed by Bayer as Nexavar for treating Kidney and Liver Cancer. Patent on Sorafenib is granted in India on 03.03.2008 having number IN 215758. This will be … Continue reading NATCO FILES INDIA’S FIRST COMPULSORY LICENSING APPLICATION

Read more »

Anti Cancer drug: Making it Patient-driven, not Disease-driven

11th April, 2011 - 10:16 am Categories: Patent Commercialisation Pharma- biotech- Patent Commercialisation

Introduction: French compatriots Ipsen and bioMérieux, have been few most potential companies, since 2007 in the development of companion assay to assess patient benefit from a compound useful for treating several severe forms of cancers.Partnership between two companies has focused on the two main broad areas of pharma research: Personalized medicine and Theronostics. Personalized medicine … Continue reading Anti Cancer drug: Making it Patient-driven, not Disease-driven

Read more »

Roche’s Struggle Over its Patents in India – Two suits, Two oppositions

27th July, 2010 - 4:47 am Categories: Patent Litigation Pharma/Biotech Patent Litigations

The struggle between innovator pharmaceutical companies (mostly in the Western world) and developing world Generic companies has been lately played out in India and especially for the last 2-3 years in the form of litigations and oppositions. Here I would be discussing the specific case of Roche (a Swiss Pharma Company) showcasing its journey of … Continue reading Roche’s Struggle Over its Patents in India – Two suits, Two oppositions

Read more »

EMERGING IP LANDSCAPE FOR GENERIC PHARMA COMPANIES: A CASE STUDY

5th July, 2010 - 6:01 am Categories: Patent Litigation Pharma/Biotech Patent Litigations

IP Issues that concern generic pharma companies generally center on ANDA filing, Patent Litigation, Patent Outlicensing and Brand Acquisitions. It has been very rare for an Indian generic player to be involved into all the four aspects in a single case involving a common drug molecule. One such case with India headquartered Sun Pharma as … Continue reading EMERGING IP LANDSCAPE FOR GENERIC PHARMA COMPANIES: A CASE STUDY

Read more »

Indian Pharmaceutical Industry Licensing Deals: Case Studies

14th June, 2010 - 10:36 am Categories: Patent Commercialisation Pharma- biotech- Patent Commercialisation

Glenmark Pharmaceuticals Glenmark, research-driven, global, integrated pharmaceutical company with Research Focus on Inflammatory Diseases, Metabolic Disorders and Pain has a presence in over 80 countries around the world. The Company has a proven track record of entering into Licensing deals with Big Pharma and entered into Outlicensing deals in 2004 with Forest laboratories for Oglemilast, … Continue reading Indian Pharmaceutical Industry Licensing Deals: Case Studies

Read more »

Categories

Archives